• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on pharmacotherapy >Cinacalcet HCl: a novel therapeutic for hyperparathyroidism.
【24h】

Cinacalcet HCl: a novel therapeutic for hyperparathyroidism.

机译：盐酸西那卡塞：一种新型的甲状旁腺功能亢进疗法。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Hyperparathyroidism (HPT) is a significant clinical concern for patients with a variety of diseases, notably the secondary HPT associated with chronic kidney disease requiring dialysis. Secondary HPT is associated with elevated para-thyroid hormone (PTH) levels, decreased levels of 1,25 dihydroxyvitamin D, and disordered mineral levels (usually high calcium and phosphorus). If not controlled, secondary HPT can result in bone disease, vascular calcification, and ultimately, patient mortality. Established, conventional therapies, such as 1,25dihydroxyvitamin D analogues (vitamin D analogues) and phosphate binders, have proven to be inadequate in enabling patients to meet the National Kidney Foundation's-Kidney Disease Outcomes Quality Initiative (NKF-K/DOQI) treatment goals for PTH, calcium and phosphorus levels. A novel therapeutic, cinacalcet HCl (formerly AMG 073; Sensipar in the US and Mimpara in Europe; Amgen, Inc.), binds directly to the calcium-sensing receptor (CaR) on the cells of the parathyroid gland, increasing the receptor's sensitivity to calcium and reducing PTH, serum calcium and phosphorus levels. Treatment with cinacalcet in clinical trials has safely and effectively improved achievement of the NKF-K/DOQI goals. Cinacalcet has also reduced serum calcium levels in patients with primary HPT, including parathyroid carcinoma, in the clinical trial setting. Evidence suggesting the utility of cinacalcet in these diseases and the potential for additional therapeutic applications will be discussed.
机译：甲状旁腺功能亢进症（HPT）对于患有多种疾病（尤其是与需要透析的慢性肾脏病相关的继发性HPT）的患者而言，是一项重大的临床问题。继发性HPT与甲状旁腺激素（PTH）水平升高，1,25二羟基维生素D水平降低以及矿物质水平紊乱（通常是高钙和磷）有关。如果不加以控制，继发性HPT会导致骨病，血管钙化，并最终导致患者死亡。公认的传统疗法，例如1,25二羟基维生素D类似物（维生素D类似物）和磷酸盐结合剂，不足以使患者达到国家肾脏基金会的“肾脏疾病预后质量计划”（NKF-K / DOQI）的治疗目标用于PTH，钙和磷水平。一种新型的治疗性西那卡塞盐酸盐（曾为AMG 073;美国为Sensipar，欧洲为Mimpara; Amgen，Inc.）直接与甲状旁腺细胞上的钙敏感受体（CaR）结合，从而增强了该受体对甲状旁腺的敏感性钙和降低PTH，血清钙和磷水平。在临床试验中使用西那卡塞治疗可以安全有效地改善NKF-K / DOQI目标的实现。在临床试验中，西那卡塞特还降低了包括甲状旁腺癌在内的原发性HPT患者的血清钙水平。有证据表明西那卡塞在这些疾病中的实用性以及其他治疗应用的潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号